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Abstract: In 90% of pancreatic ductal adenocarcinoma cases, genetic alteration of the proto-oncogene
Kras has occurred, leading to uncontrolled proliferation of cancerous cells. Targeting Kras has
proven to be difficult and the battle against pancreatic cancer is ongoing. A promising approach to
combat cancer was the discovery of the clustered regularly interspaced short palindromic repeat
(CRISPR)/CRISPR-associated (Cas) system, which can be used to genetically modify cells. To assess
the potential of a CRISPR/CRISPR-associated protein 9 (Cas9) method to eliminate Kras mutations in
cells, we aimed to knock-out the c.35G>A (p.G12D) Kras mutation. Therefore, three cell lines with
a heterozygous Kras mutation (the human cell lines SUIT-2 and Panc-1 and the cell line TB32047
from a KPC mouse model) were used. After transfection, puromycin selection and single-cell
cloning, proteins from two negative controls and five to seven clones were isolated to verify the
knock-out and to analyze changes in key signal transduction proteins. Western blots showed a
specific knock-out in the KrasG12D protein, but wildtype Kras was expressed by all of the cells. Signal
transduction analysis (for Erk, Akt, Stat3, AMPKα, and c-myc) revealed expression levels similar
to the wildtype. The results described herein indicate that knocking-out the KrasG12D mutation
by CRISPR/Cas9 is possible. Additionally, under regular growth conditions, the knock-out clones
resembled wildtype cells.
Keywords: CRISPR/Cas9 system; G12D; Kras; Suit-2; Panc-1; TB32047
1. Introduction
Pancreatic cancer (PaCa) is the fourth leading cause of all cancer death in the United States
of America and Germany. Smoking, chronic pancreatitis, heavy alcohol consumption or genetic
predispositions, such as Lynch syndrome, are only a small variety of risk factors. Common symptoms,
including weight loss, abdominal or back pain, mean that identification during the early stages can be
difficult. With its disastrous five-year survival rate of about 8%, the chances of survival after diagnosis
are remote. Besides chemotherapy or radiation therapy as therapeutic options to alleviate pain or
extend survival, the only potentially curative prospect remains resection [1–4]. Therefore, a better
understanding of the functions of the tumor is fundamental to develop new treatment strategies and
identify new therapeutic targets.
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In about 90% of PaCa cases, a Kras mutation is detectable [5]. Kras is a proto-oncogene first
discovered and identified in Kirsten rat sarcoma virus. It is part of the G-protein family. In contrast
to most heterotrimeric G proteins, Kras is monomeric. As a central element in multiple signaling
pathways, it is involved in the regulation of cell proliferation, differentiation, and survival. A point
mutation in the protein leads to impairment of guanosine triphosphate (GTP)ase activity and thus
continuous transmission of non-existent growth signals [6]. Activated mutations in the proto-oncogene
Kras are a hallmark of PaCa. Its activity leads to a major role in PaCa initiation but its importance in
maintaining the tumor is uncertain [7–9].
In recent years, whole-genome sequencing led to the discovery of clustered regularly interspaced
short palindromic repeat (CRISPR) sequences and CRISPR-associated (Cas) genes in various bacteria
and archaea [10]. The identification of these sequences, resembling DNA from viruses or plasmids,
suggests that it is a bacterial adaptive immune system that provides particular defense against viral
intruders [11–13]. CRISPR-associated protein 9 (Cas9) is the most commonly used among the Cas
proteins. Cas9-mediated cleavage of DNA operates with two RNAs: (i) CRISPR-RNA (crRNA), which
recognizes foreign DNA through a complementary region 20-base pairs (bps) in length, called the
proto-spacer adjacent motif (PAM), and (ii) trans-acting CRISPR-RNA (tracrRNA), which hybridizes
with the crRNA [14,15]. To facilitate this system, the crRNA–tracrRNA fusion can be combined into
a chimeric single-guide RNA (sgRNA) [16]. By creating a 20-nucleotide region complementary to
a DNA sequence of interest in the sgRNA, Cas9 can be aimed at any genomic locus with a suitable
PAM sequence. After DNA tracking and cleavage, repair mechanisms can provoke insertion and
deletion mutations (indels), which may cause a knock-out [17]. With CRISPR/Cas9 providing a new
opportunity for modifying genes in general and the armed with the knowledge of overexpression of
Kras in PaCa, the possible knock-out of mutated Kras was investigated.
2. Results
2.1. Expression of KrasG12D and Total Ras after CRISPR/Cas9-Mediated Knock-Out in PaCa Cell Lines
To verify the role of mutant Kras in pancreatic cancer cell lines, two human (Panc-1 and SUIT-2)
and a murine cell line (TB32047) were used to perform a CRISPR/Cas9-based knock-out of the mutated
allele. All cell lines contained a heterozygous KRASG12D (c.35G>A) mutation. After transfection,
puromycin selection and single-cell cloning, we produced about five to seven clones (Kras clones).
Western blotting was performed to detect the knock-out effects introduced with the CRISPR/Cas9 gene
editing system. In all tested cell lines, the results showed a knock-out with no protein expression of
mutant protein KrasG12D. However, a normal total Kras protein expression level was observed for
Panc-1 wildtype (WT) cell lines, negative controls (transfected with nonsense sgRNA molecules; NCs)
and Kras clones. In the SUIT-2 cell line, WT and Kras clones resembled each other, whereas the protein
expression in the negative controls was higher. Total Kras expression in the TB32047 clones was lower
than in the WT and negative controls (Figure 1).
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Figure 1. Kras expression by wildtype cells, negative controls and clones in Panc-1, SUIT-2 and TB32047
cell lines. (A) Western blots (WBs) showed similar bands in Panc-1. (B) SUIT-2 negative controls
(N; pX) expressed more Kras protein th n wildtype (WT) cells and clones. (C) TB32047 clones produced
slightly less Kras protein than their WT and NC. No protein expression, indicating KrasG12D knock-out,
could be observed in Panc-1, SUIT-2 and TB32047 cell lines. β- ctin, glycerald hyde 3-phosphate
deh drogenase (GAPDH) served as l ading controls.
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2.2. DNA Sequencing from Knocked-Out Clones
DNA sequencing was performed on all knock-out clones to confirm the presence of the target
mutation in the sequence of KrasG12D. All knock-out clones had indel mutations in the sequence of
KrasG12D. Most clones (Panc-1 2.1, 2.2, 2.8 and 2.9; SUIT-2 1.6, 2.7, 2.8, and 1.10; TB32047 1.7, 1.12, 1.14,
and 1.18) had small indels (< 20 bp), while Panc-1 clones 2.7 and 2.14 had single-nucleotide insertions.
Only three clones, one from each cell line (Panc-1 2.4, SUIT-2 2.4 and TB32047 1.8), had large indels
(>20 bp) (see Table 1).
Table 1. Insertion and deletion mutation (indel) size of Panc-1, SUIT-2 and TB32047 clones. Indel size
varies between single nucleotide indel, small: < 20 base pair (bp) and large > 20 bp inserts
and/or deletions.
Panc-1 Clones Indel Size SUIT-2 Clones Indel Size TB32047 Clones Indel Size
2.1 small 1.6 small 1.7 small
2.2 small 2.7 small 1.12 small
2.4 large 2.8 small 1.14 small
2.7 single nucleotide 1.10 small 1.8 large
2.8 small 2.4 large 1.18 small
2.9 small
2.14 single nucleotide
2.3. Expression of Key Signal Transduction Proteins in CRISPR/Cas9-Edited PaCa Cell Lines
After confirming the KrasG12D protein knock-out, the effect on key signal transduction pathways
was analyzed. Specifically, the (non-)phosphorylated proteins Erk, Akt, Stat3, AMPKα and c-myc were
evaluated (Figure 2). We observed a heterogeneous expression pattern. Within Panc-1 cell clones pErk
levels remained comparatively stable, however pAkt, pStat3, pAMPKα and c-myc levels were reduced
in some Kras clones. This is contrary to the findings from the other cell lines. In the human cell line
SUIT-2, we observed a loss of Akt phosphorylation while Erk phosphorylation was retained. pStat3
and pAMPKα proteins were only produced by clone 2.6 and c-myc levels were reduced in some Kras
clones. However, within the murine KPC cell line TB32047, we found that the pErk levels and the
phosphorylation of Akt and c-myc remained constant, the pStat3 protein was only produced by two
clones, and most of the clones expressed pAMPKα.
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Figure 2. Expression of Erk, Akt, Stat3, AMPKα and c-myc proteins by wildtype cells, negative
controls and Kras clones in Panc-1, SUIT-2 and TB32047 cell lines. Here, the prefix “p” indicates the
phosphorylated version of the protein. (A) Panc-1 2.1, 2.8 and 2.14 expressed slightly less Erk than the
others. Clone 2.1 also produced less pErk. Akt expression in Panc-1 showed no difference between
WT, NC and clones. pAkt was reduced in Panc-1 clones 2.8, 2.9 and 2.14. Stat3 was expressed by all
Panc-1 clones, except 2.14. Panc-1 showed reduced pStat3 expression in clone 2.1, 2.8 and 2.14. Lower
AMPKα expression could be observed in Panc-1 WT, NC and clone 2.1. The pAMPKα expression level
was lower in clone 2.1 than the other samples. Panc-1 NC and 2.1 produced less c-myc compared to
the others. (B) SUIT-2 clones expressed Erk similar to the wildtype cells. SUIT-2 clones 1.6 and 2.7
produced less pErk. Akt expression in SUIT-2 cells showed no difference in expression between WT,
NC and clones. Only WT cells, NC and clone 2.8 expressed pAkt. Clone 1.10 produced decreased
Stat3 levels. pStat3 was only produced by SUIT-2 WT, pX2 and clone 2.6. Lower AMPKα expression
could be observed in clones 1.10 and 2.4 compared to the WT cells. Just SUIT-2 pX2 and clone 2.6
produced pAMPKα. SUIT-2 clones 1.6, 2.7 and 2.4 produced less c-myc compared to the others. (C) Erk
expression in TB32047 clones was similar to the wildtype. pErk was only expressed by TB32047 NC.
Akt, pAkt, Stat3, AMPKα and c-myc protein levels were similar throughout all TB32047 samples.
pStat3 was only produced by TB32047 NC, clones 1.12 and 1.18. TB32047 clones 1.12, 1.14, 1.8 and 1.18
expressed higher pAMPKα than the remaining samples. β-Actin, GAPDH and Na,K-ATPase served as
loading controls.
2.4. TB32047 RNA Sequencing Results
Since the edited TB32047 cells demonstrated some changes in the expression levels of key signal
transduction proteins, we further investigated the differential gene expression of the CRISPR/Cas9
knock-out in this model system. RNA sequencing (RNA-seq) data from eight TB32047 samples (WT,
N3, N4, sg1.7, sg1.8, sg1.12, sg1,14, and sg1.18) were analyzed to determine RNA expression changes
in the KrasG12D knock-outs. Based on their whole transcriptomes, the WT and NC samples grouped
together and differed from the KrasG12D knock-out samples (see Figure 3A). A total of 417 genes were
differentially expressed between the two sample groups (see Supplementary data). Principal component
analysis (PCA) based on the expression of the differentially expressed genes (DEGs) confirmed that
most of the variance in the data (69.9%, PC1) was associated with expression changes between the
KrasG12D knock-out samples and the WT and NC samples (PC1, see Figure 3B). In addition, KrasG12D
knock-out samples were separated into two groups, although these differences were comparatively
smaller (9.4% of the variance, PC2). Approximately half of the DEGs (218) were up-regulated, while
the other half (199) were down-regulated (see Figure 3C). Among the down-regulated DEGs were
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Lamb1 (log2 fold-change = −5) and Slc27a6 (log2 fold-change = −7, Figure 3D). Functional and pathway
analysis of the DEGs (see Supplementary Data) revealed that genes that were down-regulated in
the KrasG12D knock-out samples were enriched in biological processes, such as regulation of cell
migration, differentiation, and proliferation, whereas genes that were up-regulated in the KrasG12D
knock-out samples were associated with inflammatory response, regulation of the ERK1/ERK2 cascade,
and angiogenesis. Furthermore, up-regulated DEGs were enriched in the PI3K-Akt signaling pathway.
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3. Discussion
As part of the G-protein family, Kras is involved in the regulation of cell proliferation and survival.
Inactivation of its GTPase activity, as a result of mutation in the protein, leads to hyperactive effector
signaling. Therefore, mutated Kras plays a major role in and is the driver of PaCa initiation. Mouse
models have shown that an elevated frequency of activation in Kras leads to precursor lesions and the
onset of PaCa [9,18,19]. However, if Kras is required for maintenance of PaCa remains to be elucidated.
We were able to successfully knock-out KrasG12D using the CRISPR/Cas9 gene editing system
in all of the three analyzed Kras heterozygous cell lines (Panc-1, SUIT-2 and TB32047). Interestingly,
the cell cultivation showed no apoptosis or growth arrest, only a decreased growth rate compared to
the wildtype could be observed. This could be due to knocking-out mutated Kras, which can result in
a slower growth ability.
We verified the knock-outs using DNA sequencing and western blotting (WB). However,
we observed no changes in the expression level of total Kras. These results suggest that Kras is
not important for maintaining PaCa cells in vitro [9].
Furthermore, we looked for changes in key signaling pathways, such as mitogen-activated protein
kinase (MAPK) or PI3K/Akt, which are known to be the major effector pathways of Kras activation.
Our work indicates that the knock-out of KrasG12D does not affect one common pathway of signal
transduction, but that each cell line displays different effects. Others state that PI3K/Akt hyperactivation
is important in PaCa cells lacking Kras [8]. But Panc-1 and TB32047 clones exhibited different expression
patterns, while SUIT-2 clones were homogenously deficient in pAkt. The origin (human vs. mouse)
could be one of the reasons why the outcome is different. Still, TB32047 cells are genetically engineered
with a defined set of modification at Kras and p53.
If the clones are not using MAPK or PI3K/Akt pathway to survive, how can they resist apoptosis?
Besides Erk and Akt, we analyzed the signal transduction proteins Stat3, AMPKα and c-myc. Stat3 has
an anti-apoptotic effect induced by TGF-beta and is engaged in cell survival, whereas c-myc regulates
cell cycle progression, cell growth, and apoptosis [20]. Our results showed a heterozygous expression
of pStat3 among all clones from each cell line. In contrast, c-myc was stably expressed in Panc-1 and
TB32047 clones. Some of the SUIT-2 clones expressed less c-myc than others. AMPKα influences
metabolism by increasing catabolism and decreasing anabolism [21]. This is an important factor for
cell survival, but expression of pAMPKα was hetergeneous just as pStat3. This leads to the assumption
that every clone has evolved and should be considered individually.
Through RNA sequencing, we gained insight into the changed gene expression of edited TB32047
clones. We identified 417 differentially expressed genes. Two heavily down-regulated genes were
Laminin B1 (Lamb1) and solute carrier family 27, member 6 (Slc27a6). As part of a subunit which
assembles to a heterotrimeric isoform, Lamb1 facilitates cell differentiation, motility, adhesion and—as
a ligand of the laminin receptor—it enables the ability of tumor cells to invade and build vessels [22].
Slc27a6 is member of a fatty acid transport protein family which uptakes long-chain fatty acids. This is
important for energy metabolism and other cellular processes (i.e., signal transduction) [23]. After
KrasG12D knock-out these two necessary genes are down-regulated, which could negatively affect
intensive angiogenesis, invasion and energy supply and therefore provide a useful tool to combat PaCa.
Nevertheless, Kapoor et al. showed that, after KrasG12D repression in mice, pancreatic tumors
can relapse. KrasG12D-independent tumors proliferated through Yap1/Tead2 activation. Therefore,
overexpression of YAP1 may also promote growth in cells lacking Kras. This evasion could indicate
that PaCa cells are able to grow using a different mechanism [24]. This correlation and the analysis
of chemotherapy drug resistance are to be investigated in further experiments. Since confirming
the possibility to knock-out KrasG12D, a next step could be to examine interactions between different
pathways through taking aim at various targets in a multiplexed CRISPR/Cas reaction. sgRNA
combinations can be used to increase knock-out efficiency [25].
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4. Materials and Methods
4.1. Cell Culture
The human cell lines Panc-1 and SUIT-2 and the murine cell line TB32047 were used in this study.
The Panc-1 cell line was bought from ATCC® (American Type Culture Collection, Manassas, VA,
USA; CRL-1469™, RRID:CVCL_0480). Panc-1 cells were cultured in Roswell Park Memorial Institute
(RPMI) medium 1640 (ThermoFisher, Langenselbold, Germany; 21875-034). The SUIT-2 cell line was
purchased from Japanese Collection of Research Bioresources Cell Bank (JCRB1094, RRID:CVCL_3172).
SUIT-2 cells were cultured in minimum essential medium (MEM; ThermoFisher, Langenselbold
Germany, 31095-029). The TB32047 cell line was obtained with courtesy from Prof. Dave Tuveson,
Cold Spring Harbor Laboratory. TB32047 cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM; ThermoFisher, Langenselbold Germany, 30966-021). Every culture medium was enriched
with a final concentration of 10% fetal bovine serum (FBS) (ThermoFisher, Langenselbold Germany,
A31608-01). All cell lines were grown under sterile conditions to avoid contamination. For cultivation
the cells were incubated in monolayer culture at 37 ◦C, 5% CO2 and 80% air humidity. All cells
were harvested by treatment with 0.25% trypsin-ethylenediaminetetraacetic acid (trypsin-EDTA;
ThermoFisher, Langenselbold Germany, 25200-072).
4.2. CRISPR/Cas9 Gene Editing
In this study, KrasG12D was knocked out by the CRISPR/Cas9 gene editing system. The following
primers were synthesized by Eurofins Genomics: Hs_KRASm_sg1-forward (5′-CACCGTAGTTGGA
GCTGATGGCGT-3′), Hs_KRASm_sg1-reverse (5′-AAACACGCCATCAGCTCCAATAC-3′),
Hs_KRASm_sg2-forward (5′-CACCGCTTCTGGTAGTTGGAGCTGA-3′), Hs_KRASm_sg2-reverse
(5′-AAACTCAGCTCCAACTACCACAAGC-3′). Cloning was performed using pSpCas9(BB)-2A-
Puro (PX459) V2.0 vector, which was a gift from Feng Zhang (Addgene plasmid #62988;
http://n2t.net/addgene:62988; RRID:Addgene_62988) [26]. The ligated vector was inserted into E.cloni®
10G electrocompetent cells (BioCat, Heidelberg, Germany). Plasmid construction was performed
according to protocol and confirmed by sequencing. The above-mentioned cell lines were transfected
with KrasG12D knock-out plasmid by Lipofectamine® 3000 Transfection reagent (ThermoFisher,
Langenselbold Germany; #L3000015) for 24 h. After one day the transfected cells were selected with
puromycin (concentration 5 ng/µL). Mouse epidermal growth factor (mEGF) was added to the clone
culture medium. Thereafter, single-cell cloning was performed in a 96-well plate to grow single clones.
After growth, western blot and sequencing were performed to detect the knock-out.
4.3. Western Blot
To analyze the protein expression of the genetically modified cell clones, the cells were lysed
using radioimmunoprecipitation assay (RIPA) buffer. The protein concentration was determined
photometrically using Pierce® BCA Protein Assay Kit. Gel electrophoresis was performed with Bolt™
4–12% Bis-Tris Plus Gels (ThermoFisher, Langenselbold Germany, #NW04122BOX) and proteins were
transferred to a nitrocellulose membrane. After blocking with 5% milk, the following primary antibodies
were used: Akt (pan) (Cell Signaling Technology, Leiden, The Netherlands; #4691, RRID:AB_915783),
phospho-Akt (Ser 473) (CST, #9271, RRID:AB_329825), AMPKα (CST, #5831, RRID:AB_10622186),
phospho- AMPKα (Thr172) (CST, #2535, RRID:AB_331250), c-myc (CST, #5605, RRID:AB_1903938),
p44/42 MAPK (Erk1/2) (CST, #4695, RRID:AB_390779), phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)
(CST, #4370, RRID:AB_2315112), Ras (CST, #3339, RRID:AB_2269641), Ras (G12D Mutant Specific)
(CST, #14429, RRID:AB_2728748), Stat3 (CST, #12640, RRID:AB_2629499), phospho-Stat3 (Tyr705) (CST,
#9145, RRID:AB_2491009). β-Actin (CST, #8457, RRID:AB_10950489), glyceraldehyde 3-phosphate
dehydrogenase (GAPDH; CST, #5174, RRID:AB_10622025) and Na,K-adenosine triphosphate (ATP)ase
(CST, #3010, RRID:AB_2060983) served as loading controls. As secondary antibodies, horseradish
peroxidase (HRP)-linked anti-mouse immunoglobulin G (IgG) (CST, #7076, RRID:AB_330924) and
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HRP-linked anti-rabbit IgG (CST, #7074, RRID:AB_2099233) were utilized. The signals were detected
with an Amersham Imager 600 with SignalFire™ (Elite) ECL Reagent (Cell Signaling Technology,
Leiden, The Netherlands, #6883 or #12757). All western blot assays were performed more than three
times to validate the reliability of the results.
4.4. Confirmation of CRISPR/Cas9-Mediated Knock-out
To isolate DNA from the cell lines, NucleoSpin® Tissue (MACHEREY-NAGEL, Düren, Germany)
was used according to the manufacturer’s protocol. The DNA concentration was determined using
the NanoDrop 2000 (ThermoFisher, Langenselbold Germany). PCR products for sequencing were
amplified using Platinum™ SuperFi™ PCR Master Mix (ThermoFisher, Langenselbold Germany).
PCR fragments were displayed using gel electrophoresis. The following primers were used for
the human cell lines: hKras_f1 (AAGCGTCGATGGAGGAGTTT) and hKras_r1 (ACCCTCTCAC
GAAACTCTGA); and for the murine cell line Mm_Kras_f1 (ACTCTGTACATCTGTAGTCACTG) and
Mm_Kras_r1 (GCACGCAGACTGTAGAGCA) were used. PCR fragments were cloned into pMiniT
2.0 with the NEB® PCR Cloning Kit (New England Biolabs, Frankfurt, Germany, E1202). For each
single cell clone 10 bacteria colonies were picked and plasmid DNA was isolated (GeneJET Plasmid
Miniprep Kit, K0503, ThermoFisher, Langenselbold Germany). Plasmid DNA was sequenced by
Eurofins Genomics and the resulting sequences were aligned using Snapgene (GSL Biotech LLC;
Chicago, IL, USA).
4.5. RNA Isolation and Preparation
The NucleoSpin® RNA Plus kit (MACHEREY-NAGEL, Düren, Germany) was used to isolate RNA
from the cell lines according to the manufacturer’s protocol. The RNA concentration and pureness
were determined using a 2100 Bioanalyzer using the Agilent RNA 6000 Nano Kit (Agilent, Waldbronn,
Germany; 5067-1511).
4.6. RNA Sequencing
Profiling of whole-genome transcriptomic patterns was performed with 500 ng of high-quality total
RNA per sample by RNA sequencing at the next generation sequencing (NGS) core unit of the Medical
Faculty of the FAU Erlangen. Libraries of the samples were generated using the Illumina stranded
mRNA library kit. After sequencing on an Illumina HiSeq-2500 platform, the sequences were assigned
to their sample of origin according to the used indices. The quality of reads was assessed using FastQC
v0.11.4 [27]. Adapter sequences and stretches with low quality were removed using trimmomatic
v0.36 [28] with the settings HEADCROP:13 CROP:85 LEADING:20 TRAILING:20 AVGQUAL:20
MINLEN:25. Reads were mapped to the mouse reference genome (Ensembl GRCm38) [29] using
corresponding gene model annotation (v85) with STAR v2.5.3 [30] with parameters: –runThreadN 8
–genomeDir –readFilesIn –sjdbGTFfile –sjdbOverhang 100 –outSAMtype BAM SortedByCoordinate
–outFileNamePrefix –quantMode TranscriptomeSAM GeneCount. Samtools v1.6 [31] was used to
further process BAM files. Expression matrices were generated using RSEM v1.3.0 [32]. Differential
expression analysis was performed for protein-coding genes using the R/Bioconductor package DESeq2
v1.16.1 [33] with standard parameters. WT, N3 and N4 were used as controls. Genes exhibiting a false
discovery rate (FDR) ≤ 0.05 and a log2 fold-change ≥ 2 or ≤ −2 were considered differentially expressed.
Normalized rlog-transformed gene counts were calculated using the DESeq2’s rlog() function.
4.7. Functional and Pathway Analysis
Functional and pathway analysis was performed with the Database for Annotation and Integrated
Discovery (DAVID Bioinformatics Resources 6.8; http://david.abcc.ncifcrf.gov/) [34,35]. In particular,
we focused on the ontologies: KEGG pathways, Biological Processes (BP), Molecular Function (MF)
and Cellular Component (CC). Terms associated with a FDR ≤ 0.05 were considered statistical
significantly enriched.
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5. Conclusions
In conclusion, the CRISPR/Cas gene editing system can be used to knock-out KrasG12D in human
and mouse cell lines. This leads to cell clones that exhibit different aspects of Kras signal transduction.
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